Nivolumab

Nivolumab is a human monoclonal antibody (IgG4) that is used to treat several types of cancer, including melanoma, non-small cell lung cancer, renal cell carcinoma and Hodgkin’s lymphoma. It works by blocking the activity of a protein known as PD-1, which is involved in regulating the immune system. By doing this, it helps the patient’s own immune system to better recognize and attack the cancer cells. Nivolumab has been found to be effective at slowing tumor growth and prolonging patient survival, making it an important treatment option for many cancer patients. Additionally, nivolumab is generally well tolerated and has fewer side effects than other more traditional methods of cancer treatment.